Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Dec 8;273(1):10.
doi: 10.1007/s00415-025-13557-4.

Safety and effectiveness of risdiplam in adults with spinal muscular atrophy: a systematic review

Paolo Alonge #  1 , Guido Urbano #  2 , Giulio Gadaleta  3
Affiliations

Safety and effectiveness of risdiplam in adults with spinal muscular atrophy: a systematic review

Paolo Alonge et al. J Neurol. .

Abstract

Background: Risdiplam has broadened therapeutic options for spinal muscular atrophy (SMA). While its efficacy and safety are well established in children, data in adults remain limited. This review summarizes current evidence on risdiplam use in the adult SMA population.

Methods: Following PRISMA 2020 guidelines, we systematically reviewed PubMed, Scopus, and the Cochrane Library up to September 2025 for studies including risdiplam-treated adults (≥ 18 years). Outcomes were summarized across motor, bulbar, respiratory, patient-reported, safety, and adherence domains.

Results: Fourteen studies (> 200 adults, mainly SMA types 2 and 3) were included. Most participants were non-ambulant and treatment naïve. Motor function was generally stable, with modest yet significant improvements on RULM, HFMSE, or MFM-32, particularly among younger/less severely affected adults. Swallowing, speech, and fatigue often improved even in advanced disease. Patient-reported outcomes consistently indicated perceived gains in quality of life across all phenotypes. Adverse events were mostly mild and transient-mainly gastrointestinal symptoms, photosensitivity, or liver enzyme elevations-with very few temporary discontinuations.

Conclusions: Risdiplam shows a favorable safety profile and provides both disease stabilization and multidimensional benefits across all functional phenotypes in adults with SMA, although further longitudinal studies using standardized outcome measures are needed to clarify its long-term impact.

Keywords: Adult SMA; Effectiveness; Risdiplam; Safety.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflicts of interest: P.A. has received speaker fees from Teva. G.G. has received speaker fees from Biogen and Roche. G.U. has received speaker fees from Roche.

Figures

Fig. 1
Fig. 1
PRISMA flow diagram in the study selection process. Source: Page MJ, et al. BMJ 2021;372:n71. https://doi.org/10.1136/bmj.n71. This work is licensed under CC BY 4.0. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/
See this image and copyright information in PMC

References

    1. Mercuri E, Sumner CJ, Muntoni F, Darras BT, Finkel RS (2022) Spinal muscular atrophy. Nat Rev Dis Prim 8(1):52 - DOI - PubMed
    1. Mercuri E, Cicala G, Villa M, Pera MC (2025) What did we learn from new treatments in SMA? A narrative review. Acta Myol 44(1):28–32 - PMC - PubMed
    1. Hagenacker T, Paradis AD, Lawson-Michod KA, Youn B (2025) Systematic review and meta-analysis of long-term Nusinersen effectiveness in adolescents and adults with spinal muscular atrophy. Adv Ther 42(9):4143. 10.1007/s12325-025-03260-1 - DOI - PMC - PubMed
    1. Mercuri E, Deconinck N, Mazzone ES, Nascimento A, Oskoui M, Saito K et al (2022) Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurol 21(1):42–52 - DOI - PubMed
    1. Dhillon S (2020) Risdiplam: first approval. Drugs 80(17):1853. 10.1007/s40265-020-01410-z - DOI - PubMed

Publication types

LinkOut - more resources